Aquestive Therapeutics has resubmitted its New Drug Application for Anaphylm, a sublingual film for severe allergic reactions, to the FDA. This follows a Complete Response Letter in January 2026, which requested a confirmatory pharmacokinetic study and a human factors study, both of which the company has now completed.
Aquestive Therapeutics has officially resubmitted its New Drug Application for Anaphylm to the FDA, addressing the issues raised in a previous Complete Response Letter (CRL). This is a significant step forward for the company, as it indicates progress towards potential market approval for a key product. The company successfully completed the requested confirmatory pharmacokinetic study and human factors study, which were the primary hurdles. For traders, this resubmission reduces regulatory uncertainty and could lead to a positive re-rating of AQST stock if the FDA ultimately approves Anaphylm. The short-term implication is a potential upward movement in stock price due to increased confidence, while the long-term implication is the revenue potential from a new, innovative allergy treatment.